Lexaria Bioscience (LEXX) Other financing activities (2021 - 2025)
Lexaria Bioscience's (LEXX) quarterly Other financing activities came in at $167219.0 in Q1 2025, up 155.74% quarter-over-quarter from -$300000.0 in Q2 2022.
Lexaria Bioscience (LEXX) Other financing activities (2021 - 2025) Analysis & Trends
Lexaria Bioscience has disclosed Other financing activities across 3 years of filings, most recently posting $167219.0 for Q1 2025.
- Other financing activities for Q1 2025 came in at $167219.0, changed N/A year-over-year; the trailing twelve-month figure through Feb 2025 was $1.2 million (changed N/A YoY), and the FY2021 annual result was $85000.0, changed N/A from the prior year.
- Other financing activities came in at $167219.0 for Q1 2025 at Lexaria Bioscience, up from -$300000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $1.2 million in Q1 2022 to a low of -$300000.0 in Q2 2022.
- The 3-year median for Other financing activities is $126109.5 (2021), against an average of $288054.8.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2025 | 167,219.00 |
| Feb 28, 2025 | 167,219.00 |
| May 31, 2022 | -300,000.00 |
| May 31, 2022 | -300,000.00 |
| Feb 28, 2022 | 1.20 Mn |
| Feb 28, 2022 | 1.20 Mn |
| Aug 31, 2021 | 85,000.00 |
| Aug 31, 2021 | 85,000.00 |